Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s ...

Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

Janssen-Cilag Limited has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya, Janssen-Cilag Limited) for use in adults with Crohn’s disease and ulcerative colitis (UC).

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC). The approval was granted on 16th May, 2025 to ...

The U.K.’s Medicines and Healthcare products Regulatory Agency has approved guselkumab, or Tremfya, to treat Crohn’s disease ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Tremfya (guselkumab) (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC).

Johnson & Johnson (J&J) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its ...